Xipra Sublingual Tablet contains Piroxicam 20 mg, a nonsteroidal anti-inflammatory drug (NSAID) belonging to the oxicam class, indicated for the management of pain and inflammation associated with musculoskeletal disorders such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. The sublingual formulation allows for rapid absorption through the oral mucosa, resulting in a faster onset of action compared to conventional oral tablets. Piroxicam exerts its therapeutic effects by inhibiting cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing the synthesis of prostaglandins responsible for pain, inflammation, and fever. Xipra is particularly useful in patients requiring prompt relief from acute pain episodes or those who have difficulty swallowing conventional tablets. The recommended dosage should be individualized based on the severity of symptoms and patient response, with caution advised in patients with a history of gastrointestinal ulceration, bleeding disorders, renal or hepatic impairment, and cardiovascular risk factors. Common adverse effects may include gastrointestinal discomfort, nausea, dizziness, and hypersensitivity reactions. It is contraindicated in patients with known hypersensitivity to piroxicam or other NSAIDs. Concomitant use with other NSAIDs or anticoagulants should be avoided or closely monitored. Xipra Sublingual Tablet should be used under medical supervision to ensure optimal efficacy and safety.